Restriction Spectrum Imaging (RSI) improves cancer detection

November 18, 2023
< 1 mins

Category: Published research
Product: OnQ Prostate
Disease: Prostate cancer

Compares the diagnostic performance of restriction spectrum imaging (RSI), with that of conventional multi-parametric (MP) magnetic resonance imaging (MRI) for prostate cancer (PCa) detection in a blinded reader-based format. 2016.

[button]Download[/button]

Topic: Published research

More Resources

09/16/2025

OnQ Prostate for Focal Therapy

Read how OnQ Prostate supports focal therapy by personalizing prostate cancer care for patients while minimizing the risks associated with it.

Blogs

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

Blogs, Product updates

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

Blogs

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

Blogs

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

Blogs

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

Our solutions

Our solutions

About

Support

Resources